Literature DB >> 3753979

Formation of meizothrombin as intermediate in factor Xa-catalyzed prothrombin activation.

J Rosing, R F Zwaal, G Tans.   

Abstract

The conversion of prothrombin into thrombin by Factor Xa requires the cleavage of two peptide bonds in prothrombin. Dependent on the order of cleavage, prethrombin 2 or meizothrombin occurs as intermediate. Since prethrombin 2 has as yet been the only observed intermediate, prothrombin activation is generally considered to proceed via prethrombin 2. In this paper we present new methods that allow differentiation between meizothrombin and thrombin formed during the initial phase of prothrombin activation. These methods, which make use of the different reactivities of meizothrombin and thrombin toward fibrinogen and antithrombin III plus heparin, enabled us to show the generation of considerable amounts of meizothrombin during Factor Xa-catalyzed prothrombin activation. Both meizothrombin and thrombin incorporated the active site-directed fluorescent chloromethyl ketone 5-dimethylaminonaphthalene-1-sulfonyl-Glu-Gly-Arg-CH2Cl. Gel electrophoretic analysis of chloromethyl ketone-treated aliquots of prothrombin activation mixtures confirmed meizothrombin formation. These observations demonstrate that prothrombin may also be converted into thrombin via meizothrombin.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3753979

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Occlusion of anion-binding exosite 2 in meizothrombin explains its impaired ability to activate factor V.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2018-12-21       Impact factor: 5.157

2.  Comparison of the active-site conformations of bovine alpha-thrombin and meizothrombin(desF1) by electron spin resonance.

Authors:  P D Boxrud; L J Berliner
Journal:  J Protein Chem       Date:  1996-02

3.  Notecarin D binds human factor V and factor Va with high affinity in the absence of membranes.

Authors:  Jennifer L Newell-Caito; Malabika Laha; Anthony C Tharp; Jonathan I Creamer; Hong Xu; Ashoka A Maddur; Guido Tans; Paul E Bock
Journal:  J Biol Chem       Date:  2011-09-12       Impact factor: 5.157

4.  Amide H/2H exchange reveals a mechanism of thrombin activation.

Authors:  Julia R Koeppe; Elizabeth A Komives
Journal:  Biochemistry       Date:  2006-06-27       Impact factor: 3.162

5.  Prothrombin activation on the activated platelet surface optimizes expression of procoagulant activity.

Authors:  Jeremy P Wood; Jay R Silveira; Nicole M Maille; Laura M Haynes; Paula B Tracy
Journal:  Blood       Date:  2010-12-03       Impact factor: 22.113

6.  Active site-labeled prothrombin inhibits prothrombinase in vitro and thrombosis in vivo.

Authors:  Heather K Kroh; Peter Panizzi; Svetlana Tchaikovski; T Regan Baird; Nancy Wei; Sriram Krishnaswamy; Guido Tans; Jan Rosing; Bruce Furie; Barbara C Furie; Paul E Bock
Journal:  J Biol Chem       Date:  2011-04-29       Impact factor: 5.157

7.  Expression of allosteric linkage between the sodium ion binding site and exosite I of thrombin during prothrombin activation.

Authors:  Heather K Kroh; Guido Tans; Gerry A F Nicolaes; Jan Rosing; Paul E Bock
Journal:  J Biol Chem       Date:  2007-04-12       Impact factor: 5.157

8.  Protein C activation on endothelial cells by prothrombin activation products generated in situ: meizothrombin is a better protein C activator than alpha-thrombin.

Authors:  T M Hackeng; G Tans; S J Koppelman; P G de Groot; J Rosing; B N Bouma
Journal:  Biochem J       Date:  1996-10-15       Impact factor: 3.857

9.  Prothrombin amino terminal region helps protect coagulation factor Va from proteolytic inactivation by activated protein C.

Authors:  Subramanian Yegneswaran; Phuong M Nguyen; Andrew J Gale; John H Griffin
Journal:  Thromb Haemost       Date:  2009-01       Impact factor: 5.249

10.  Limiting prothrombin activation to meizothrombin is compatible with survival but significantly alters hemostasis in mice.

Authors:  Maureen A Shaw; Keith W Kombrinck; Kathryn E McElhinney; David R Sweet; Matthew J Flick; Joseph S Palumbo; Mei Cheng; Naomi L Esmon; Charles T Esmon; Alexander Brill; Denisa D Wagner; Jay L Degen; Eric S Mullins
Journal:  Blood       Date:  2016-06-01       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.